|Born||1959 (age 58–59)|
|Known for||former CEO, Teva Pharmaceutical Industries|
In February 2017, Teva announced that Vigodman was stepping down as CEO with immediate effect and would be replace on an interim basis by the chairman, Yitzhak Peterburg, and Sol Barer would be the new chairman. This was a consequence of the $40 billion acquisition of Activis' generics division, which sent Teva spiralling down and saw its market capitalisation cut in half in less than a year. He is succeeded by Kåre Schultz, a Danish pharmaceutical veteran.